Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-30
2010-12-28
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S128000, C514S007600, C514S008500, C424S185100, C536S023100, C435S069100, C435S069700, C435S070100, C435S183000
Reexamination Certificate
active
07858576
ABSTRACT:
Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.
REFERENCES:
patent: 4309776 (1982-01-01), Berguer
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4749570 (1988-06-01), Poznansky
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5258453 (1993-11-01), Kopecek et al.
patent: 5356804 (1994-10-01), Desnick et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5405942 (1995-04-01), Bell et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5476779 (1995-12-01), Chen et al.
patent: 5549892 (1996-08-01), Friedman et al.
patent: 5580757 (1996-12-01), Desnick et al.
patent: 5633234 (1997-05-01), August et al.
patent: 5633235 (1997-05-01), Townsend
patent: 5704910 (1998-01-01), Humes
patent: 5736363 (1998-04-01), Edwards et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5817623 (1998-10-01), Ishii
patent: 5817789 (1998-10-01), Heartlein et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5854025 (1998-12-01), Edwards et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5981194 (1999-11-01), Jefferies et al.
patent: 6020144 (2000-02-01), Gueiros-Filho et al.
patent: 6027921 (2000-02-01), Heartlein et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6083725 (2000-07-01), Selden et al.
patent: 6118045 (2000-09-01), Reuser et al.
patent: 6226603 (2001-05-01), Freire et al.
patent: 6235874 (2001-05-01), Wu et al.
patent: 6262026 (2001-07-01), Heartlein et al.
patent: 6270989 (2001-08-01), Treco et al.
patent: 6273598 (2001-08-01), Keck et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6284875 (2001-09-01), Turpen et al.
patent: 6329501 (2001-12-01), Smith et al.
patent: 6344436 (2002-02-01), Smith et al.
patent: 6348194 (2002-02-01), Huse et al.
patent: 6441147 (2002-08-01), Turpen et al.
patent: 6451600 (2002-09-01), Rasmussen et al.
patent: 6455494 (2002-09-01), Jefferies et al.
patent: 6472140 (2002-10-01), Tanzi et al.
patent: 6537785 (2003-03-01), Canfield
patent: 6566099 (2003-05-01), Selden et al.
patent: 6569661 (2003-05-01), Qin et al.
patent: 6596500 (2003-07-01), Kang et al.
patent: 7396811 (2008-07-01), LeBowitz et al.
patent: 2001/0006635 (2001-07-01), Bennett et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2002/0013953 (2002-01-01), Reuser et al.
patent: 2002/0081654 (2002-06-01), Sandrin et al.
patent: 2002/0110551 (2002-08-01), Chen
patent: 2002/0142299 (2002-10-01), Davidson et al.
patent: 2003/0004236 (2003-01-01), Meade
patent: 2003/0021787 (2003-01-01), Hung et al.
patent: 2003/0077806 (2003-04-01), Selden et al.
patent: 2003/0082176 (2003-05-01), LeBowitz et al.
patent: 2004/0005309 (2004-01-01), LeBowitz et al.
patent: 2004/0006008 (2004-01-01), LeBowitz et al.
patent: 2004/0029779 (2004-02-01), Zhu et al.
patent: 2004/0081645 (2004-04-01), Van Bree et al.
patent: 2004/0248262 (2004-12-01), Koeberl et al.
patent: 2005/0026823 (2005-02-01), Zankel et al.
patent: 2005/0058634 (2005-03-01), Zhu
patent: 2005/0281805 (2005-12-01), LeBowitz et al.
patent: 0196056 (1986-10-01), None
patent: 0466222 (1992-01-01), None
patent: 0599303 (1994-06-01), None
patent: WO-9104014 (1991-04-01), None
patent: WO-9114438 (1991-10-01), None
patent: WO-9222332 (1992-12-01), None
patent: WO 93/06216 (1993-04-01), None
patent: WO-9310819 (1993-06-01), None
patent: WO-9402178 (1994-02-01), None
patent: WO-9502421 (1995-01-01), None
patent: WO 00/53730 (2000-09-01), None
patent: WO 01/19955 (2001-03-01), None
patent: WO-0153730 (2001-07-01), None
patent: WO-0256907 (2002-07-01), None
patent: WO-02087510 (2002-11-01), None
patent: WO-03032727 (2003-04-01), None
patent: WO-03032913 (2003-04-01), None
patent: WO 03/057179 (2003-07-01), None
patent: WO-03102583 (2003-12-01), None
patent: WO-2005078077 (2005-08-01), None
patent: WO 02/44355 (2006-06-01), None
Barton et al., Proc Natl Acad Sci U S A. Mar. 1990;87(5):1913-1916.
Achord, et al., “Human β-Glucuronidase: In Vivo Clearance and in Vitro Uptake by a Glycoprotein Recognition System on Reticuloendothelial Cells,”Cell, 15: 269-278 (Sep. 1978).
Achord et al., “Human β-Glucuronidase. II. Fate of Infused Human Placental β-Glucuronidase in the Rat,”Pediat. Res., 11: 816-822 (1977).
Allen et al., “Metabolic Correction of Fucosidosis Lymphoid Cells by Galaptin-α-L-Fucosidase Conjugates,”Biochemical and Biophysical Research Communications, 172(1):335-340 (Oct. 15, 1990).
Authier et al., “In vitro endosome-lysosome transfer of dephosphorylated EGF receptor and Shc in rat liver,”FEBS Letters, 00:25-31 (1999).
Bach et al., “Binding of Mutants of Human Insulin-like Growth Factor II to Insulin-like Growth Factor Binding Proteins 1-6,”The Journal of Biological Chemistry, 268(12):9246-9254 (May 5, 1993).
Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules,” inMolecular Recognition: Chemical and Biological Problems, 182-196 (1989).
Baxter, R.C., “Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.”Am. J. Physiol. Endocrinol. Metab., 278:E967-E976 (2000).
Beutler et al., “Gaucher Disease,” inThe Metabolic and Molecular Bases of Inherited Disease, 8thed., 3635-3668 (2001).
Bickel et al., “Delivery of peptides and proteins through the blood-brain barrier,”Advanced Drug Delivery Reviews, 46(1-3):247-279 (2001).
Bijsterbosch et al., “Native and modified lipoproteins as drug delivery systems,”Advanced Drug Delivery Reviews, 5:231-251 (1990).
Birkenmeier et al., “Increased Life span and Correction of Metabolic Defects in Murine Mucopolysaccharidosis Type VII After Syngeneic Bone Marrow Transplantation,”Blood, 78(11):3081-3092 (1991).
Birkenmeier et al., “Murine Mucopolysaccharidosis Type VII, Characterization of a Mouse with β-Glucuronidase Deficiency,”J. Clin. Invest., 83(4):1258-1266 (Apr. 1989).
Blakey et al., “Effect of Chemical Deglycosylation of Ricin A Chain on the in Vivo Fate and Cytotoxic Activity of an Immunotoxin Composed of Ricin A Chain and Anti-Thy 1.1 Antibody,”Cancer Research, 47: 947-952 (Feb. 1987).
Braulke, T., “Type-2 IGF Receptor: A Multi-Ligand Binding Protein,”Horm. Metab. Res., 31:242-248 (1999).
Brooks, “Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models,”Molec. Genet. And Metab., 68: 268-275 (1999).
Brown et al., “Structure of a functional IGF2R fragment determined from the anomalous scattering of sulfur,”The EMBO Journal, 21(5):1054-1062 (2002).
Bürgisser et al., “Mutants of Human Insulin-like Growth Factor II with Altered Affinities for the Type 1 and Type 2 Insulin-like Growth Factor Receptor,”The Journal of Biological Chemistry, 266(2):1029-1033 (Jan. 15, 1991).
Cacciari et al., “Somatomedin C in Pediatric Pathophysiology,”Pediatrician, 14: 146-153 (1987).
Calhoun et al., “Fabry disease: Isolation of a cDNA clone encoding human α-galactosidase A,”Proc. Natl. Acad. Sci. USA, 82:7364-7368 (Nov. 1985)..
Cascieri et al., “Structural Analogs of Human Insulin-like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors,”The Journal of Biological Chemistry, 264(4):2199-2202 (Feb. 5, 1999).
Connolly-Martin, Y., “Computer-Assisted Rational Drug Design,”Methods in Enzymology, 203: 587-613 (1991).
Daly et al., “Neonatal gene transfer leads to widespread correction of pathology in a murine mod
Beverley Stephen M.
LeBowitz Jonathan H.
Chen Fangli
Choate Hall & Stewart LLP
Gamett Daniel C
Nickol Gary B.
ZyStor Therapeutics, Inc.
LandOfFree
Method for targeting lysosomal enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for targeting lysosomal enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for targeting lysosomal enzymes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159856